A multicenter, open-label trial of low dose naltrexone for prevention of cervical cancer

Trial Profile

A multicenter, open-label trial of low dose naltrexone for prevention of cervical cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 May 2017 According to an Immune Therapeutics media release, The company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines, the application will include results of four phase II clinical trials and one bridging trial clinical trial.
    • 16 Sep 2016 New trial record
    • 23 Aug 2016 According to an Immune Therapeutics media release, Dr, Frank Taulo from the OBGYN Department of Queen Elizabeth Central Hospital in Blantyre is the Principle Investigator of thsi trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top